Ikarian Capital’s Tvardi Therapeutics TVRD Stock Holding History

Ikarian Capital’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-117	Closed	-$68K	–	180
2019 Q4	$68K	Buy	+117	New	+$82.1K	0.01%	110

Other funds holding TVRD

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AFG

American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

SAM

Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

DWAM

Duncan Williams Asset Management Memphis, Tennessee $444M AUM 24.78% 1-Year Est. Return

Ikarian Capital's TVRD Position: Q3 2021 in Review

Ikarian Capital sold out of Tvardi Therapeutics (TVRD) in Q3 2021, closing a stake of 815 shares — an estimated $418K sold.

Ikarian Capital first reported a position in TVRD in Q1 2020 and held it in 6 quarters. The position peaked at $12.1M in Q1 2021. 169 funds tracked by Wall St. Rank hold TVRD as of Q3 2021.

Ikarian Capital reported no remaining Tvardi Therapeutics position as of Q3 2021 after selling out during the quarter.
Ikarian Capital sold 815 Tvardi Therapeutics shares in Q3 2021, an estimated $418K.
Ikarian Capital first reported a position in Tvardi Therapeutics in Q1 2020 and held it in 6 quarters.
Ikarian Capital's Tvardi Therapeutics position peaked at $12.1M in Q1 2021.
169 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q3 2021.

Based on Ikarian Capital's 13F filing for Q3 2021, filed 15 Nov 2021.